BPC-157 vs P21
Extensively Studied vs Emerging
compatible No known negative interactions; different mechanisms.
Molecular Data
BPC-157 P21
Weight 1,419.53 Da ~1,100 Da
Half-life <30 minutes Over 3 hours (mouse plasma)
Chain 15 amino acids —
Type Pentadecapeptide CNTF-derived peptide
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
P21
01 Potent promotion of neurogenesis in the dentate gyrus
02 Increased BDNF expression
03 Reduced tau protein pathology
04 Reduced amyloid-beta plaque formation
05 Improved cognitive function and memory
06 Restored synaptic deficits in cortex and hippocampus
07 Reduced mortality rate in AD models
08 Crosses blood-brain barrier effectively
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
P21
Research compound - dosing not established for humans / Daily in animal research protocols
Research protocol Variable by study Daily
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
P21
Limited data - primarily preclinical research
Generally well-tolerated in animal studies
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Not approved for human use
Pregnancy or breastfeeding
Unknown safety profile in humans
Research Evidence
BPC-157 P21
Status Extensively Studied Emerging
References 6 studies 4 studies
Latest January 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.